Dopamine D 3 receptors are preferentially localized in the limbic system and midbrain, and thus may be involved in the pathophysiology of neuropsychiatry disorders. [
Introduction
Dysregulation of the dopaminergic system is implicated in several pathological conditions, including schizophrenia (Seeman & Lee, 1975 ), Parkinson's disease (Cotzias, 1968) , depression (Bunney et al. 1971) and drug addiction (Di Chiara & Imperato, 1988) . Dopamine receptors are G-protein-coupled receptors which are classified into two distinct dopamine receptor subtypes : the D 1 -like (D 1 and D 5 receptors) and the D 2 -like (D 2 , D 3 , and D 4 receptors). Recent research has focused on the D 3 receptor because of its restricted distribution in the limbic regions of the brain (Gurevich & Joyce, 1999 ; Murray et al. 1992 Murray et al. , 1994 .
In contrast to other dopamine receptors, the D 3 receptor has a unique 'rigid ' configuration as evidenced by the difficulty that GTP analogues [e.g. GppNHp (guanilylimidodiphosphate)] have in shifting it from a high-affinity state to a low-affinity state (Vanhauwe et al. 2000) . This characteristic may contribute to the very high affinity the D 3 receptor shows for dopamine (at least 20-fold higher than that of the D 2 receptor) (Freedman et al. 1994 ; Sokoloff et al. 1992) , and also suggests that in vivo this receptor may be occupied by endogenous dopamine for extended periods of time. Moreover, given its high affinity for dopamine, the D 3 receptor may be activated by tonic (background) dopamine levels in the brain (Levesque et al. 1992) , which may attenuate any effects of dopamine fluctuation related to phasic dopamine release. Accordingly, small changes in the number or function of D 3 receptors may lead to dramatic effects on synaptic transmission, suggesting that the D 3 receptor may be a critical modulator of normal brain function. In addition, a single nucleotide polymorphism (313A>G) within the first exon of the human D 3 receptor gene results in a change in the amino acid at position 9 of the protein from serine to glycine (Ser9Gly). Compared with the Ser variant, the Gly variant has a 4-to 5-fold greater affinity for dopamine, as well as for some D 3 receptor antagonists (Jeanneteau et al. 2006 ; Lundstrom & Turpin, 1996) . Thus, the Ser9Gly polymorphism may also play an important role in D 3 receptor agonist and antagonist pharmacology.
Until recently, the in-vivo study of D 3 receptors in humans has been hindered by the failure to develop a D 3 receptor radiotracer for positron emission tomography (PET) imaging (Sovago et al. 2004 (Sovago et al. , 2005 . 11 C](+)-PHNO has rarely been explored in vitro and never in vivo. The published in-vitro data indicate a 30-to 50-fold selectivity of D 3 over D 2 receptors when no difference in the G-protein-coupled state is considered (Freedman et al. 1994 ; van Vliet et al. 2000) . In addition, a less than ideal unpublished in-vitro study described a selectivity of approximately 150-fold higher affinity for the D 3 than D 2 receptor (Parker et al. 2006) . In contrast, Seeman et al. (2005) reported (+)-PHNO K i values of 0.6 nM for the D 3 receptor and 0.24 nM for the D 2 receptor, both in the high-affinity state for dopamine (G-protein-coupled state), indicating that (+)-PHNO has a 3-fold greater affinity at the high-affinity state of the D 2 receptor than at the high-affinity state of the D 3 receptor. This last finding disagrees with the available in-vivo and ex-vivo data using [
11 C](+)-PHNO or [ 3 H](+)-PHNO that suggest a preferential affinity for D 3 receptors (GraffGuerrero et al. 2009 a ; Narendran et al. 2006 ; Rabiner et al. 2009 ). Therefore, the relevance of in-vitro or ex-vivo data is uncertain, especially since considerable discrepancies between in-vivo and in-vitro affinities have also been described (Ekelund et al. 2007 ; McCormick et al. 2009 ).
To date, there are no human data in healthy controls on the displacement of [
11 C](+)-PHNO by a D 3 receptor selective or preferential compound. ABT-925, also known as A-437203 or BSF-201640, is a D 3 receptor antagonist with 45-to 120-fold higher in-vitro affinity for the D 3 than the D 2 receptor (Chaperon et al. 2003 ; Geneste et al. 2006 ; Gross et al. 1997 Gross et al. , 2006 . 
Methods

Participants
Twenty healthy, right-handed male volunteers were recruited for this study. Subjects were aged 18-40 yr, had a body mass index between 18 and 26 kg/m 2 , had no major medical problems based on a clinical interview, had normal basic laboratory tests and electrocardiograms, and absence of any psychiatric disorder based upon the Mini-International Neuropsychiatric Interview version 5.0.0 (Sheehan et al. 1998) . Subjects were only included if they declared themselves to have abstained from tobacco or any other nicotinecontaining products within the 6 months prior to inclusion, had abstained from alcohol or caffeine within 3 d prior to study PET scans, and had a negative urine screen for drugs of abuse or alcohol at the initial assessment. All the subjects were confined at a phase 1 unit starting the evening prior to any PET scan procedure where smoking was not allowed. Written informed consent was obtained after full explanation of the study procedures and risks. The study was approved by the local Ethics Committee of the Centre for Addiction and Mental Health and the Canadian Ministry of Health.
Study design
The overall design is shown in Fig. 1 . During the screening visit, inclusion and exclusion criteria were assessed, and a blood sample was drawn in order to assess D 3 receptor genotype. During the qualification visit, subjects' tolerance to a single 600-mg dose of ABT-925 was evaluated as a criterion for continuing in the study. The MRI visit took place at any time following successful completion of the qualification visit and before PET visit 3. During PET visit 1, subjects underwent the baseline [
11 C](+)-PHNO PET scan. During PET visits 2 and 3, subjects received a single, pre-determined oral dose of ABT-925 90 min prior to the injection of [
11 C](+)-PHNO. The 90-min interval was chosen as it corresponds to the mean T max for oral ABT-925, which persists at a plateau for the entire duration of PET scanning (Fig. 6 ). ABT-925 doses were selected to allow the generation of an ABT-925 plasma level/receptor occupancy curve that would efficiently achieve the scientific goals of the study (dose description in Table 1 ). ABT-925 tablets were taken in 50-mg multiples to achieve the designated dose. The sample size in this study was selected based on our previous experience and is consistent with similar studies in the literature (Mamo et al. 2007 ; Takano et al. 2006) . Due to the exploratory nature of this study, subjects were enrolled, and the study was to be continued with escalating doses (to a pre-specified maximum) as long as ABT-925 was observed to produce measurable changes in [
11 C](+)-PHNO BP ND and until at least 13 subjects completed three visits.
ABT-925 plasma levels
Plasma levels of ABT-925 were assessed at 120 min after the administration of ABT-925 during the PET scans. Blood samples were collected into K + EDTA collection tubes and centrifuged within 1 h of collection to separate the plasma. Each plasma sample was frozen and shipped to Abbott Laboratories for subsequent quantification. ABT-925 concentrations were measured using a validated LC-MS/MS assay with a lower limit of quantification of 0.01 mg/ml.
Genotyping
DNA was isolated from whole blood using the FlexiGene DNA AGF3000 kit (Qiagen, USA) on the AutogenFlex 3000 (AutoGen, USA) instrument. Genotypes for the DRD3 313A>G SNP (Ser9Gly ; rs6280) were determined using the pyrosequencing detection method (Pyrosequencing Inc., USA), using the following oligonucleotides : PCR forward primer, ATCACGCACCTCCCTCTGG ; PCR reverse primer, biotin-GCTGGCACCTGTGGAGTTCT ; and pyrosequencing primer, TCTGAGCCAGCTGAGT.
Radiochemistry for [
11
C](+)-PHNO
The radiosynthesis of [ 11 C](+)-PHNO has been described in detail elsewhere (Wilson et al. 2005) . Briefly, [
11 C]propionyl chloride was reacted with 9-hydroxynaphthoxazine to generate an [ 11 C]amide, which was subsequently reduced by lithium aluminium hydride. Purification by HPLC and formulation gave >98 % radiochemically pure [
11 C](+)-PHNO as a sterile, pyrogen-free solution suitable for human studies.
PET image acquisition
PET studies were performed using a high-resolution head-dedicated PET camera system, CPS-HRRT (Siemens Medical Imaging, USA), which measures radioactivity in 207 brain slices with a thickness of 1.2 mm each. This camera system consists of eight panel detectors, each panel being composed of 117 phoswich detectors, arranged 13 in the axial plane by 9 in the radial plane. The in-plane resolution of the scanner was y2.8 mm full-width at halfmaximum (FWHM). Transmission scans were acquired using a 137 Cs (T1 /2 =30.2 yr, E=662 keV) single photon point source to provide attenuation correction, and the emission data were acquired in list mode. The raw data were reconstructed by filteredback projection. A custom-fitted thermoplastic mask (Tru-Scan Imaging, USA) was made for each subject and used with a head fixation system during PET scans in order to reduce any movement during the acquisition. After subjects were placed on the C](+)-PHNO was injected as a bolus, followed by a flush with 2 ml saline into an intravenous line placed in an antecubital vein. No statistical differences were observed among dose (F 2,44 =2.14, p=0.12), specific activity (F 2,44 =2.82, p=0.07) and mass (F 2,44 =0.77, p=0.46) between PET scan sessions (details per subject in Table 1 ). Scanning time was 90 min in list mode, and then 30 frames were defined : 1-15 of 1-min duration and 16-30 of 5-min duration.
MRI imaging
The MRI scans were performed in a 1.5 T Signa GE scanner to acquire a proton density image (TE=17 ms, TR=6000 ms, FOV=22r22 cm, 256r256 slice thickness of 2 mm, number of excitations=2) for each subject.
PET image analysis
Region of interest (ROI)-based analysis
Time-activity curves from ROIs were obtained from the dynamic [
11 C](+)-PHNO PET images in native space. ROI were defined on MRI images co-registered to the PET image in native space. ROIs included substantia nigra, globus pallidus, caudate, putamen, ventral striatum (Mawlawi et al. 2001) and cerebellar cortex (hereafter referred to as cerebellum). The coregistration of the MRI to the PET space image was done using the normalized mutual information algorithm (Studholme et al. 1997) as implemented in SPM2 (SPM2, Wellcome Department of Cognitive Neurology, London ; http://www.fil.ion.ucl.ac.uk/ spm). Time-activity curves were obtained using inhouse software for semi-automated generation of ROIs (Rusjan et al. 2006) . To obtain a quantitative estimate of binding, time-activity curves were analysed using the Simplified Reference Tissue Method (SRTM ; Lammertsma & Hume, 1996) , using the cerebellum as the reference region. This method has been validated to reliably estimate the BP ND , which compares the concentration of radioligand in the receptor-rich region to that in the receptor-free region (Innis et al. 2007) , and has also been validated to estimate the BP ND for [ 11 C](+)-PHNO (Ginovart et al. 2007) .
Voxel-wise analysis
Parametric voxel-wise BP ND maps from the dynamic images in native space were generated according to the method of Gunn et al. (1997) , with the cerebellum as reference region and as implemented in PMOD version 2.7 software (PMOD Technologies Ltd, Switzerland). The BP ND map images were spatially normalized into the Montreal Neurological Institute (MNI) brain space by nearest neighbour interpolation and with a voxel size fixed in 2r2r2 mm using SPM5 software (Friston, 1995) . The normalized images were smoothed with a Gaussian filter in each coordinate direction with a kernel of 3 mm.
Receptor occupancy calculations
Receptor occupancy was defined as the percentage of reduction of the BP ND from the baseline (i.e. drug-free) state to the ABT-925-exposed state : % Occupancy= BP ND baselinexBP ND ABT-925 BP ND baseline r100:
Estimation of ED 50 and ceiling (D 2 and D 3 fractions)
The data from the oral ABT-925 doses and plasma levels at 120-min post-dose (expected plasma maximum levels) were fitted to one-site and two-site binding models, described by the following equations : One-site binding model : (Gurevich & Joyce, 1999 ; Murray et al. 1994) . Two-site binding model : The one-site model with common ED 50 shared across regions and the two-site model were compared using Akaike's Information Criterion (AIC) and F test as implemented in GraphPad Prism software (version 4, GraphPad Software Inc., USA).
Statistics
ROI-based analysis
The statistical analysis was made using SPSS software version 15.0 (SPSS Inc., USA). Variables were presented as mean¡standard deviation (S.D.). Comparison of receptor occupancy between ROIs was performed using an analysis of variance (ANOVA) with post-hoc Bonferroni-corrected pairwise comparisons ; homogeneity of variance between groups was assessed with Levene's test. A repeated-measures ANOVA was performed to compare the standardized radioactivity in the cerebellum (within-subjects factor) between the baseline and the ABT-925 exposed conditions (between-subjects factor). This analysis only included subjects (n=15) with 450 mg or 600 mg doses to maximize the effect ; if one subject had received both doses, only the highest was included. Comparison of BP ND per genotype was performed using a Kruskal-Wallis test for each ROI. These comparisons were performed only as an exploration of the data given the small sample for GG and SS subjects. Significance was assumed at p<0.05. Nonlinear fittings were performed with GraphPad Prism software version 4 (GraphPad Software Inc.).
Voxel-wise analysis
This analysis was performed in SPM5 to correlate the BP ND maps with plasma levels of ABT-925 at 120-min post-dose. We reported areas only if they met the joint criteria of (a) p (uncorrected)<0.001, (b) an extent o10 voxels, and (c) were in the caudate, putamen, globus pallidus, ventral striatum, midbrain or thalamus. Additionally, the statistically significant a-priori regions were corrected for multiple comparisons using the false discovery rate (FDR) approach.
Results
Twenty healthy, right-handed male volunteers were recruited for this study. Sixteen subjects underwent PET scans (13 subjects underwent three PET scans and three subjects underwent two PET scans). After the radiotracer injection, four subjects reported mild to moderate transient nausea without need of scanning interruption. Four subjects withdrew from the study prematurely due to reasons unrelated to the study. The demographic characteristics are summarized in Table 2 .
Receptor occupancy in ROIs (Fig. 2) . Statistical analysis demonstrated a significant difference in receptor occupancy by ABT-925 between ROIs (ANOVA : F 4,140 =15.02, p<0.001) ( Table 3 ). Pairwise comparison demonstrated that at almost every dose tested, receptor occupancy was higher in the 
Voxel-wise analysis
The voxel-wise correlation between BP ND and plasma levels of ABT-925 were observed in the right and left globus pallidus as detailed in Table 4 and illustrated by oral doses in Fig. 3 . 
ED 50 and ceiling estimation
Nonlinear regression analyses using the one-site and two-site binding models with a common ED 50 (D 3 ) across regions were compared, indicating that the data were better explained by the one-site binding model with a common ED 50 (D 3 ) across regions (Table 5 ). In addition, the one-site binding model with common ED 50 (D 3 ) across regions was compared with the same model without ED 50 (D 3 ) constraint (i.e. a different ED 50 for each region) ( Table 6 ). The comparison indicates a better fit to the one-site model with common ED 50 (D 3 ) across regions (F 4,134 =1.98, p=0.10 ; difference in AIC=x0.90 ; probability of correct of 61 % vs. 1.5 %). Therefore, the one-site binding model with common ED 50 (D 3 ) across regions was preferred for use in the present study. The fraction of binding attributable to D 3 receptors in the ROIs showed the following rank order of reduction : substantia nigra (100 %)>globus pallidus (90 %)>ventral striatum (62 %)>caudate (55 %)> putamen (53 %). The ED 50 (D 3 ) was 4.37 mg/ml (details in Table 5 ). The relationships of ABT-925 dose or plasma concentrations vs. receptor occupancy in the ROIs, fitted by the one-site binding model with common ED 50 (D 3 ) across regions, are illustrated in Figs 2 and 4.
Pharmacogenetics
The comparison of BP ND per genotype showed no differences between baseline BP ND dependent on the D 3 receptor genotype in any region (Table 7) .
Discussion
The present study shows for the first time in humans that [
11 C](+)-PHNO binding can be blocked by a D 3 receptor preferential antagonist in a dose-dependent manner. Moreover, the results derived from the onesite binding model indicate that the fraction of the [ 11 C](+)-PHNO binding signal attributable to D 3 receptors varies in different brain regions -from a high fraction in the substantia nigra (100 %) and globus pallidus (90 %), to a lower fraction in the ventral striatum (62 %), caudate (55 %) and putamen (53 %).
In this study, we did not observe a statistically significant impact of the Ser9Gly D 3 receptor polymorphism on the binding properties of [ 11 C](+)-PHNO. However, due to the small number of subjects, this study was not well powered for this genetic analysis, and these results should be interpreted with caution.
The results indicate that the BP ND of the D 3 receptor-rich regions (substantia nigra and globus pallidus) 11 C](+)-PHNO binding in the globus pallidus and substantia nigra is more than 70 % D 3 receptormediated. In contrast, the binding in D 2 receptor-rich areas, such as dorsal striatum (i.e. caudate and putamen), is suggested to be 10-40 % D 3 receptor-mediated (Narendran et al. 2006 ; Rabiner et al. 2009 ). The blockade of [
11 C](+)-PHNO binding shown in the present study agrees with post-mortem human data describing the density of D 3 receptors, which indicate a higher number of D 3 receptors in substantia nigra and globus pallidus (Gurevich & Joyce, 1999 ; Murray et al. 1994) . Therefore, our results confirm these findings in humans and provide more precise estimates of relative binding attributable to D 3 receptors. The model was fitted constraining the percentage of binding o0 and f100.
Our group recently performed an occupancy study with [
11 C](+)-PHNO in schizophrenia patients who were chronically treated with clozapine, olanzapine or risperidone. We demonstrated that these three antipsychotics chronically administered do not occupy The comparison of the results between the one-site and the two-site binding models, both estimated with a common ED 50 (D 3 ) across regions, indicates that our data is better described by the one-site binding model. The one site-binding model with a common ED 50 (D 3 ) across regions assumes that the binding of ABT-925 to other binding sites (e.g. D 2 receptor sites) at the dose range employed is negligible. However, when the data are fitted with the one-site binding model, but with an estimated ED 50 (D 3 ) for each region, the result showed different ED 50 (D 3 )s for each region. The reason for this discrepancy is unclear, but could be due to : (1) 11 C](+)-PHNO is an agonist, and its selectivity may be influenced by the proportion of receptors in high-and low-affinity states. Under the theoretical assumptions that the number of D 3 receptors in the dorsal striatum (caudate and putamen) is negligible, which is based on human autoradiography studies (Gurevich & Joyce, 1999 ; Murray et al. 1994) (Chaperon et al. 2003 ; Geneste et al. 2006 ; Gross et al. 1997 Gross et al. , 2006 . This discrepancy could be secondary to a high D 3 receptor signal contribution in the dorsal striatum and to a poor D 2 /D 3 receptor selectivity of [ 11 C](+)-PHNO. Nevertheless these explanations seem unlikely because SB-277011, in non-human primates, has been shown to almost completely block binding of [
11 C](+)-PHNO in the substantia nigra and globus pallidus, with a very low occupancy (<20 %) in the putamen (Rabiner et al. 2009 ). Nevertheless, the results on the extrapolated selectivity of ABT-925 should be considered with caution since they are based on several assumptions. In addition, our dataset was unable to identify a second binding site.
The D 3 receptor fraction was explicitly estimated by the one-site binding model with a common ED 50 (D 3 ) across regions and indicates that in the substantia nigra and the globus pallidus (100 % and 90 %, respectively) most of the [ 11 C](+)-PHNO signal corresponds to the D 3 receptor. This observation is in accordance with the D 3 receptor fractions reported in rodent midbrain (100 %) and ventral pallidum (87 %), as well as in non-human primate midbrain (91 %) and globus pallidus (68 %), in similar experiments employing SB-277011 as a D 3 receptor blocker (Rabiner et al. 2009 ). Therefore, the substantia nigra and globus pallidus seem to be suitable regions in which to perform D 3 receptor occupancy studies employing [
11 C](+)-PHNO as a radiotracer. The results of this study, based on the comparison between the ED 50 values from D 3 and D 2 receptor-rich regions, suggest that the magnitude of the ratio selectivity of ABT-925 for the D 3 vs. the D 2 receptor as shown in vivo in humans is not as high as that measured during in-vitro conditions. The reason for this discrepancy has still to be elucidated. However, discrepancies between in-vivo and in-vitro affinities have been previously observed during radiotracer development (Ekelund et al. 2007) , and also in humans receiving antipsychotics (Graff-Guerrero et al. 2009a) . A possible explanation is that different proportions of receptors configured in the high-affinity state (G-protein-coupled state) in vivo vs. in vitro may be responsible for the observed differential selectivity of an agonist radiotracer such as [
11 C](+)-PHNO. We did not collect arterial samples to perform a full kinetic analysis. Thus, our data did not allow for the direct estimation of BP in the ROIs. This may be seen as an important potential limitation due to the following facts : (1) the quantification of cerebellar [
11 C](+)-PHNO binding in humans has shown two kinetic compartments, with the second constituting 7 % of the binding (Ginovart et al. 2007) , and (2) recent evidence from non-human primates showed a mean decrease of 13 % (S.D.=13, range 17-28 %) in the cerebellar volume of distribution after dosing with SB-277011 (Rabiner et al. 2009 ). However, the SRTM approach (Lammertsma & Hume, 1996) used in the present study has been validated for [ 11 C](+)-PHNO in humans (Ginovart et al. 2007 ) and has demonstrated good correlation between the BP ND estimated using the cerebellum as the reference region vs. the BP estimated using a full kinetic analysis. Previous data obtained in humans show no detectable change in cerebellar radioactivity accumulation after haloperidol blockade ). This finding is consistent with results from preclinical studies performed in cats with haloperidol and raclopride blockade . In addition, our data demonstrated that uptake in the cerebellum before and after ABT-925 (450-600 mg) administration did not change (Fig. 5 This study has several limitations. Because it was performed in normal male volunteers with single doses of ABT-925, any extrapolation to other populations or conditions (e.g. females, schizophrenics or chronic dosing) should be approached with caution. Another potential concern may be the lack of partial volume and movement correction, particularly in the substantia nigra, as this region is small and extremely sensitive to movement and partial volume effects. However, our within-subject occupancy estimation and the good correlation with results derived from previous rodent and non-human primate studies support the validity of the results presented here (Rabiner et al. 2009 ). In addition, recent findings comparing HRRT with HR+ scanners suggest that there is a reduction in partial volume effects with HRRT (van Velden et al. 2009 ).
Four of 16 subjects presented mild to moderate nausea within a few minutes following radiotracer injection. Nausea lasted for 3-5 min and resolved spontaneously. This side-effect is frequently observed during dopamine agonist therapy and has been associated with a direct pharmacological effect at the dopamine D 2/3 receptors in the chemotactic triggerzone (Harding et al. 1987) . Interestingly, nausea was only observed during the ABT-925-free condition (i.e. baseline PET scans). This finding is consistent with reports from previous studies during D 2/3 antagonistfree conditions (Ginovart et al. 2007 ; Graff-Guerrero et al. 2009b ; Willeit et al. 2006) . In contrast, nausea has not been observed during D 2 antagonist conditions (Graff-Guerrero et al. Our study is the first in-vivo demonstration of D 3 receptor occupancy as quantified using [
11 C](+)-PHNO in conjunction with a D 3 receptor preferential antagonist in humans. Earlier imaging studies have shown that many therapeutic compounds, particularly antipsychotics, bind preferentially to D 2 -like receptors (Farde et al. 1992 ; Kapur et al. 1996 ; Nordstrom et al. 1993 ; Pilowsky et al. 1993 ), but because D 3 receptorspecific imaging tools have been lacking, it has been difficult to establish the binding of therapeutic compounds to D 3 receptors specifically (Sovago et al. 2004 (Sovago et al. , 2005 . The data from the present study suggest that [
11 C](+)-PHNO is a promising tool for estimating in-vivo D 3 receptor occupancy in humans and may provide a means of determining the D 3 receptor antagonism of various therapeutic compounds.
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